ARTICLE | Product Development
Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C
September 30, 2020 7:01 PM UTC
Amgen has joined the syndicate of investors backing Carmot in a $47 million series C round that will advance its lead Type II diabetes candidate — a therapy developed using the same platform that spawned Amgen’s first-in-class KRAS inhibitor — through Phase II testing.
In addition to Amgen Inc. (NASDAQ:AMGN), existing investors The Column Group, Horizons Ventures and other institutional investors participated in the round. ...